Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of…
Posted: February 6, 2023 at 12:50 am
PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that its first virtual-only Annual Meeting of Stockholders (the “Meeting”) is scheduled to be held on April 6, 2023 at 9AM PST. Scilex also announced that its Board of Directors has set the close of business on March 6, 2023 as the record date (the “Record Date”) for determining stockholders entitled to notice of, and to vote at, at the Meeting.
Read the original:
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of...
Posted in Global News Feed
Comments Off on Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of…
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
Posted: January 29, 2023 at 1:02 am
January 27, 2023
Excerpt from:
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
Posted in Global News Feed
Comments Off on argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
BioSenic appoints Yves Sagot as Independent Director
Posted: January 29, 2023 at 1:02 am
REGULATED INFORMATION
Continued here:
BioSenic appoints Yves Sagot as Independent Director
Posted in Global News Feed
Comments Off on BioSenic appoints Yves Sagot as Independent Director
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic…
Posted: January 29, 2023 at 1:02 am
Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
See the rest here:
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic...
Posted in Global News Feed
Comments Off on Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic…
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
Posted: January 29, 2023 at 1:02 am
ORION CORPORATION PRESS RELEASE 27 January 2023 at 14:00 EET Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
Read more here:
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
Posted in Global News Feed
Comments Off on Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
Posted: January 29, 2023 at 1:02 am
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
Read the original here:
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
Posted in Global News Feed
Comments Off on Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
Arbutus Announces Resignation of Board Member
Posted: January 29, 2023 at 1:02 am
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notified the Company of her intention to resign from the Company’s Board of Directors, effective February 26, 2023. Dr. Tran will be transitioning into public service commencing February 27, 2023, that will preclude her participation on the Arbutus and other pharmaceutical and biotechnology Boards.
Read the original:
Arbutus Announces Resignation of Board Member
Posted in Global News Feed
Comments Off on Arbutus Announces Resignation of Board Member
Amarin to Present at SVB Securities Global Biopharma Conference
Posted: January 29, 2023 at 1:02 am
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference.
Link:
Amarin to Present at SVB Securities Global Biopharma Conference
Posted in Global News Feed
Comments Off on Amarin to Present at SVB Securities Global Biopharma Conference
Trading by management and close relations of management
Posted: January 29, 2023 at 1:02 am
Please read the full announcement in PDF
Go here to see the original:
Trading by management and close relations of management
Posted in Global News Feed
Comments Off on Trading by management and close relations of management
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
Posted: January 29, 2023 at 1:02 am
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors –
Continued here:
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
Posted in Global News Feed
Comments Off on Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance